Format

Send to

Choose Destination
Semin Cutan Med Surg. 2014 Jun;33(4 Suppl):S69-72. doi: 10.12788/j.sder.0098.

Therapeutic development in psoriasis.

Author information

1
Assistant Professor of Dermatology, Tufts School of Medicine; Director, Psoriasis Treatment Center, Skincare Physicians, Chestnut Hill, MA.
2
Clinical Professor of Dermatology, Saint Louis University Central Dermatology, St Louis, MO.

Abstract

Advances in molecular biology have provided the basis for development of new therapeutic approaches to psoriasis. New, more effective therapies target specific molecules in the inflammatory cascade involved in the pathogenesis of psoriasis.The biologic era of psoriasis therapy began with inhibitors of T-cell activation, tumor necrosis factor-α, and interleukin (IL)-12/23. Continued investigation has led to therapies and therapeutic candidates that target IL-17, IL-23, phosphodiesterase-4, and isomers of Janus kinase.

KEYWORDS:

JAK interlukin-17 inhibitors; Janus kinase inhibitors; apremilast; brodalumab; inflammation; interleukin-12/23; ixekizumab; monoclonal antibody; phosphodiesterase-4; psoriasis; secukinumab; tofacitinib; tumor necrosis factors

PMID:
25268599
DOI:
10.12788/j.sder.0098
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Frontline Medical Communications Inc
Loading ...
Support Center